At Mount Sinai, we are one of the two test centers in the United States help research and develop new biopsy technology with Invivo, A Philips Healthcare company. Dr. Rastinehad has been developing a new biopsy approach using UroNav as a transperineal platform to perform biopsies with lower infection rates. This new technology has now raised the question:
Doctor, if you can see the cancer on MRI and then biopsy it using MR US fusion guided prostate biopsy technology, why can’t you just treat those spots?
Prostate cancer is a very complicated disease for patients to understand. The issue is that not all cancers need to be treated, but others need treatment. The definition of what is clinically significant can vary depending on many factors. The difficulty for some patients is that ANY cancer to them is clinically significant. They want it treated!
Emberton and colleagues have reviewed their series of patients treated for prostate cancer and estimated ~ 50% of men could have been candidates for focal therapy. The other factor is that traditional therapies which include radiation and or surgery can be associated with urinary leakage and erectile dysfunction.
Focal therapy maybe the option that patients are looking for. It is considered the middle way, a step between active surveillance and whole gland treatment. Currently, there is no long term data regarding this new treatment approach. Focal therapy is still considered investigational; we are offering a new treatment approach that aims to help ablate (kill) prostate tissue.
What is exciting, this technology (MR US Fusion) can be combined with focal treatment approaches to now allow doctors to focus on specific areas within the prostate. A Mount Sinai, we are excited to have Dr. Rastinehad as the national principal investigator using gold nanoparticles to focally ablate prostate tissue in collaboration with Nanospectra Biosciences. The gold nanoparticles are able to selectively be deposited within hyper-vascular tumors. The clinical challenge is that when treating prostate cancer focally is that you may damage adjacent structures (prostate nerves, urethral sphincter, rectum and other structures). We are investigating ultra-focal therapy (UFT) which allows us to improve targeting for prostate ablation. If you are interested, please contact 212-241-4812 for a consult and/or email our Research Nurse, Cindy Knauer ([email protected])
For more information, please visit. We are actively recruiting patients. https://clinicaltrials.gov/ct2/show/NCT02680535.